Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...
Management delivered record-high bookings and backlog, achieving significant revenue, profit, and margin growth for the quarter, while raising full-year 2026 financial guidance on the strength of ...
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced nine presentations at the European Society of Cardiology Heart Failure 2026 Congress taking place in Barcelona, Spain, from May 9–12, 2026.
Practice-changing, Paradigm-shifting Clinical Trials in Urology (P2s): A Pivotal, Randomized, Sham-Controlled Trial of the Urocross Expander System for Treatment of LUTS due to BPH – 30 Month Safety ...
Corcept Therapeutics Incorporated is a Strong Buy after early FDA approval of Lyforli for PROC, with upside from EU decisions ...
Threat hunters are warning that the cybercriminal operation known as VECT 2.0 acts more like a wiper than a ransomware due to ...
Stoke Therapeutics, Inc.: late-stage zorevunersen for SCN1A Dravet Syndrome with durable 3-year data, Phase 3 EMPEROR and ...
Total Revenue -- $164.9 million, up from $157.2 million the previous year; reflects increasing prescriptions and patient volume. Prescription Trends -- Record levels of new prescriptions, new patient ...
The case against respondent Pedro Hernandez rested entirely on his own statements (to police and others). In 2012, after ...
Gains in best corrected visual acuity (BCVA) of +9 letters at 36 months among patients with extensive coverage of OpRegen ...
A discussion of the rapid integration of AI in the US insurance industry, the legal and ethical challenges arising from AI ...
Where people come, people go! Let me show all of these people what I know, there’s no place like home.” St. Patrick’s High ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results